间充质干细胞及其外泌体治疗肝纤维化的研究进展

摘要/Abstract

摘要： 肝纤维化是一种慢性肝脏疾病,是肝损伤发展为肝硬化并最终导致器官衰竭的重要阶段,目前,其有效治疗方案较少。间充质干细胞(MSCs)是源自各种器官的多能干细胞,可通过各种机制来减轻肝纤维化。MSCs外泌体作用的无细胞疗法引起了广泛关注,因为它们可以克服MSCs移植的局限性。本文综述了MSCs的基本特征及其治疗肝纤维化的机制,发现基因工程技术与纳米技术已被广泛用于无细胞疗法治疗肝纤维化,为MSCs改善肝纤维化以及无细胞治疗策略提供了理论基础。

姜艳贞, 张进丽, 李思思, 王钰, 马俊艳, 付兆媛. 间充质干细胞及其外泌体治疗肝纤维化的研究进展[J]. 肝脏, 2026, 31(2): 163-167.

/ 推荐

参考文献

[1] Schwabe R F, Brenner D A. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease[J].Nat Rev Gastroenterol Hepatol, 2025, 22(7):481-499.
[2] Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3):151-166.
[3] Rahimi S, Derakhshani A, Alifarsangi A, et al. Immunomodulatory effects of stem cell therapy in liver fibrosis: a systematic review[J].Iran J Allergy Asthma Immunol, 2025, 24(6):718-733.
[4] Yang X, Li Q, Liu W, et al. Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment[J].Cell Mol Immunol, 2023, 20(6):583-599.
[5] Wang Z, Zhong D, Yan T, et al. Stem cells from human exfoliated deciduous teeth-derived exosomes for the treatment of acute liver injury and liver fibrosis[J].ACS Appl Mater Interfaces, 2025, 17(12):17948-17964.
[6] Fang Y, Chen L, Yuan Y, et al. Human menstrual blood-derived stem cells secreted ECM1 directly interacts with LRP1α to ameliorate hepatic fibrosis through FoxO1 and mTOR signaling pathway[J].Stem Cell Res Ther, 2025, 16(1):230.
[7] Yi Y F, Fan Z Q, Liu C, et al. Immunomodulatory effects and clinical application of exosomes derived from mesenchymal stem cells[J].World J Stem Cells, 2025, 17(3):103560.
[8] Gong T, Liu L, Jiang W, et al. DAMP-sensing receptors in sterile inflammation and inflammatory diseases[J].Nat Rev Immunol, 2020, 20(2):95-112.
[9] Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues[J].Mol Asp Med, 2019, 65:37-55.
[10] Wang S, Li K, Pickholz E, et al. An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis[J].Sci Transl Med, 2023, 15(677):eadd3949.
[11] Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis[J].Nat Rev Gastroenterol Hepatol, 2023, 20(10):633-646.
[12] Shojaie L, Iorga A, Dara L. Cell death in liver diseases: a review[J].Int J Mol Sci,2020,21(24):9682.
[13] Huang T, Zhang C, Shang Z, et al. Bone mesenchymal stem cells improve cholestatic liver fibrosis by targeting ULK1 to regulate autophagy through PI3K/AKT/mTOR pathway[J].Stem Cells Transl Med, 2024, 13:648-660.
[14] Huang T, Nie L, Diao H, et al. Bone mesenchymal stem cells attenuate hepatic stellate cell activation and liver fibrosis through REDD1/autophagy pathway [J].Stem Cells Transl Med, 2025, 14(7):szaf023.
[15] Zhou Q, Rong C, Gu T, et al. Mesenchymal stem cells improve liver fibrosis and protect hepatocytes by promoting microRNA-148a-5p-mediated inhibition of Notch signaling pathway[J].Stem Cell Res Ther, 2022, 13(1):354.
[16] Yao Y, Xia Z, Cheng F, et al. Human placental mesenchymal stem cells ameliorate liver fibrosis in mice by upregulation of Caveolin1 in hepatic stellate cells[J].Stem Cell Res Ther, 2021, 12(1):294.
[17] Yao L, Hu X, Dai K, et al. Mesenchymal stromal cells: promising treatment for liver cirrhosis[J].Stem Cell Res Ther, 2022, 13(1):308.
[18] Cao Y, Ji C, Lu L. Mesenchymal stem cell therapy for liver fibrosis/cirrhosis[J]. Ann Transl Med, 2020, 8(8):562.
[19] Yi Q, Yang J, Wu Y, et al. Immune microenvironment changes of liver cirrhosis: emerging role of mesenchymal stromal cells[J].Front Immunol, 2023, 14:1204524.
[20] Feng X, Feng B, Zhou J, et al. Mesenchymal stem cells alleviate mouse liver fibrosis by inhibiting pathogenic function of intrahepatic B cells[J].Hepatology, 2025, 81(4):1211-1227.
[21] Li C, Jin Y, Wei S, et al. Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury[J].Hepatology, 2019, 70(5):1714-1731.
[22] Liu J, Gao J, Liang Z, et al. Mesenchymal stem cells and their microenvironment[J].Stem Cell Res Ther, 2022, 13(1):429.
[23] Chen Q H, Wu F, Liu L, et al. Mesenchymal stem cells regulate the Th17/Treg cell balance partly through hepatocyte growth factor in vitro[J].Stem Cell Res Ther, 2020, 11(1):91.
[24] Psaraki A, Ntari L, Karakostas C, et al. Extracellular vesicles derived from mesenchymal stem/stromal cells: the regenerative impact in liver diseases[J].Hepatology, 2022, 75(6):1590-1603.
[25] Tian S, Zhou X, Zheng L, et al. Engineered mesenchymal stem cell-derived small extracellular vesicles mitigate liver fibrosis by delivering USP10 to reprogram macrophage phenotype[J].Biomater Res, 2025, 29:0244.
[26] Mincheva G, Moreno-Manzano V, Felipo V, et al. Extracellular vesicles from mesenchymal stem cells improve liver injury in rats with mild liver damage. Underlying mechanisms and role of TGFβ[J].Life Sci, 2025, 364:123429.
[27] Yadav S, Maity P, Kapat K. The opportunities and challenges of mesenchymal stem cells-derived exosomes in theranostics and regenerative medicine [J].Cells, 2024, 13(23):1956.
[28] Gan L, Zheng L, Yao L, et al. Exosomes from adipose-derived mesenchymal stem cells improve liver fibrosis by regulating the miR-20a-5p/TGFBR2 axis to affect the p38 MAPK/NF-κB pathway[J].Cytokine, 2023, 172:156386.
[29] Rong X, Liu J, Yao X, et al. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway[J].Stem Cell Res Ther, 2019, 10(1):98.
[30] Tan Y, Huang Y, Mei R, et al. HucMSC-derived exosomes delivered BECN1 induces ferroptosis of hepatic stellate cells via regulating the xCT/GPX4 axis[J].Cell Death Dis, 2022, 13(4):319.
[31] Wang Z, Yuan M, Yao L, et al. Exosomal miR-499a-5p from human umbilical cord mesenchymal stem cells attenuates liver fibrosis via targeting ETS1/GPX4-mediated ferroptosis in hepatic stellate cells[J].J Nanobiotechnology, 2025, 23(1):222.
[32] Tian S, Zhou X, Zhang M, et al. Mesenchymal stem cell-derived exosomes protect against liver fibrosis via delivering miR-148a to target KLF6/STAT3 pathway in macrophages[J].Stem Cell Res Ther, 2022, 13(1):330.
[33] Tao H, Liu Q, Zeng A, et al. Unlocking the potential of mesenchymal stem cells in liver fibrosis: insights into the impact of autophagy and aging[J].Int Immunopharmacol, 2023, 121:110497.
[34] Zhang J, Lu T, Xiao J, et al. MSC-derived extracellular vesicles as nanotherapeutics for promoting aged liver regeneration[J].J Control Release, 2023, 356:402-415.
[35] Wang H Y, Li C, Liu W H, et al. Autophagy inhibition via Becn1 downregulation improves the mesenchymal stem cells antifibrotic potential in experimental liver fibrosis[J].J Cell Physiol, 2020, 235(3):2722-2737.
[36] Wang Y, Piao C, Liu T, et al. Effects of the exosomes of adipose-derived mesenchymal stem cells on apoptosis and pyroptosis of injured liver in miniature pigs[J].Biomed Pharmacother, 2023, 169:115873.
[37] Harrell C R, Volarevic V. Apoptosis: a friend or foe in mesenchymal stem cell-based immunosuppression[J].Adv Protein Chem Struct Biol, 2021, 126:39-62.
[38] Zhang Y, Zhangdi H, Nie X, et al. Exosomes derived from BMMSCs mitigate the hepatic fibrosis via anti-pyroptosis pathway in a cirrhosis model[J].Cells, 2022, 11(24):4004.
[39] Didamoony M A, Soubh A A, Ahmed L A. Cutting-edge insights into liver fibrosis: advanced therapeutic strategies and future perspectives using engineered mesenchymal stem cell-derived exosomes[J].Drug Deliv Transl Res,2025, 15(8):2608-2623.
[40] Zhang J, Qiu X, Lei Y, et al. Engineered EVs from LncEEF1G-overexpressing MSCs promote fibrotic liver regeneration by upregulating HGF release from hepatic stellate cells[J].Exp Mol Med, 2025, 57(3):584-600.
[41] Kim J Y, Park H, Park S Y, et al. Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis[J].Clin Mol Hepatol, 2025, 31(3):823-840.
[42] Zhu D, Sun Z, Wei J, et al. BMP7-Loaded human umbilical cord mesenchymal stem cell-derived small extracellular vesicles ameliorate liver fibrosis by targeting sctivated hepatic stellate cells[J].Int J Nanomedicine, 2024, 19:3475-3495.
[43] Park H W, Lee D H, Kim S, et al. Amphiphilic lipid-peptide engineered placenta-derived mesenchymal stem cells for liver fibrosis treatment[J].Asian J Pharm Sci, 2025, 20(4):101061.
[44] Mendes B B, Conniot J, Avital A, et al. Nanodelivery of nucleic acids[J].Nat Rev Methods Primers, 2022, 2:24.
[45] Fan L, Wei A, Gao Z, et al. Current progress of mesenchymal stem cell membrane-camouflaged nanoparticles for targeted therapy[J].Biomed Pharmacother, 2023, 161:114451.
[46] Tian Y, Sun D, Liu N, et al. Biomimetic mesenchymal stem cell membrane-coated nanoparticle delivery of MKP5 inhibits hepatic fibrosis through the IRE/XBP1 pathway[J].J Nanobiotechnology, 2024, 22(1):741.
[47] Xiong Z, Chen P, Wang Z, et al. Human umbilical cord-derived mesenchymal stem cells attenuate liver fibrosis by inhibiting hepatocyte ferroptosis through mitochondrial transfer[J].Free Radic Biol Med, 2025, 231:163-177.
[48] Liu W, Liu Y, Zhang L, et al. Nucleic acid spheres for treating capillarisation of liver sinusoidal endothelial cells in liver fibrosis[J].Nat Commun, 2025, 16(1):4517.
[49] Chen S, Wu Z, Zhang J, et al. Research and application of medicines for treating liver fibrosis: current status and prospects[J].Front Pharmacol, 2025, 16:1582258.